Steini, CHM has 4 trials in the clinic. 2 X CART and 2 X NK.
success with only one of these therapies will result in a valuation multiples of current valuation.
CDH17 has blockbuster potential targeting a US25 bn market with large unmet needs. If we show early signs of efficacy, mark.l my words big pharma and investors will flock to this stock.
we already had demonstrated efficacy in NK and CLTX as well as two CRs for blood cancers from NK out of 3 (?) patients - the third patient with stable disease was on a low dose of NK and not the the combo therapy in. Ph1b.
cart and nk will have a role to play for years to come. Cart costs and manufacturing will be simplified and less costly as the process is refined.
CHM Price at posting:
1.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)